WASHINGTON — Even in an election year dominated by a deadly pandemic and President Trump’s chaotic first term, Democrats in North Carolina are talking, unceasingly, about drug prices.
In a brutal series of attack ads, Democrats have painted incumbent Sen. Thom Tillis, a Republican, as a pro-pharma shill, even calling him “pharma’s favorite senator.” They’ve highlighted his status as a leading recipient of drug industry campaign cash and his recent opposition to a GOP-backed drug pricing bill. His Democratic opponent, Cal Cunningham, has highlighted Tillis’ drug pricing record throughout each of the campaign’s three debates.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
